IN2014MN02661A - - Google Patents
Info
- Publication number
- IN2014MN02661A IN2014MN02661A IN2661MUN2014A IN2014MN02661A IN 2014MN02661 A IN2014MN02661 A IN 2014MN02661A IN 2661MUN2014 A IN2661MUN2014 A IN 2661MUN2014A IN 2014MN02661 A IN2014MN02661 A IN 2014MN02661A
- Authority
- IN
- India
- Prior art keywords
- ampk
- treatment
- activators
- liver disease
- non alcoholic
- Prior art date
Links
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 abstract 4
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 abstract 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 4
- 239000012190 activator Substances 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000032928 Dyslipidaemia Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000017170 Lipid metabolism disease Diseases 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010038923 Retinopathy Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000019425 cirrhosis of liver Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000006575 hypertriglyceridemia Diseases 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000007823 neuropathy Effects 0.000 abstract 1
- 201000001119 neuropathy Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305775.4A EP2679591A1 (en) | 2012-06-29 | 2012-06-29 | Thienopyridone derivatives useful as activators of AMPK |
| PCT/EP2013/063741 WO2014001554A1 (en) | 2012-06-29 | 2013-06-28 | Thienopyridone derivatives useful as activators of ampk |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02661A true IN2014MN02661A (it) | 2015-08-28 |
Family
ID=48703549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2661MUN2014 IN2014MN02661A (it) | 2012-06-29 | 2013-06-28 |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9284329B2 (it) |
| EP (2) | EP2679591A1 (it) |
| JP (1) | JP5972460B2 (it) |
| KR (1) | KR101704448B1 (it) |
| CN (2) | CN107266467A (it) |
| AU (1) | AU2013283239B2 (it) |
| BR (1) | BR112014032526B1 (it) |
| CA (1) | CA2876789C (it) |
| CY (1) | CY1118213T1 (it) |
| DK (1) | DK2867240T3 (it) |
| EA (1) | EA026300B1 (it) |
| ES (1) | ES2603737T3 (it) |
| HR (1) | HRP20161482T1 (it) |
| HU (1) | HUE030946T2 (it) |
| IL (1) | IL236221A (it) |
| IN (1) | IN2014MN02661A (it) |
| LT (1) | LT2867240T (it) |
| ME (1) | ME02537B (it) |
| MX (1) | MX359221B (it) |
| PL (1) | PL2867240T3 (it) |
| PT (1) | PT2867240T (it) |
| RS (1) | RS55308B1 (it) |
| SI (1) | SI2867240T1 (it) |
| SM (1) | SMT201600418B (it) |
| WO (1) | WO2014001554A1 (it) |
| ZA (1) | ZA201500593B (it) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105078992B (zh) * | 2014-05-23 | 2017-11-21 | 资元堂生物科技股份有限公司 | 异喹啉生物碱衍生物用于制备促进ampk活性的药物的用途 |
| CN105037321A (zh) * | 2015-06-23 | 2015-11-11 | 佛山市赛维斯医药科技有限公司 | 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途 |
| CN104910130A (zh) * | 2015-06-23 | 2015-09-16 | 佛山市赛维斯医药科技有限公司 | 一种含六甲基苯环和氨基苯结构的黄原酸酯类化合物、其制备方法及用途 |
| CN104892569A (zh) * | 2015-06-23 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途 |
| CN104945370A (zh) * | 2015-06-23 | 2015-09-30 | 佛山市赛维斯医药科技有限公司 | 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途 |
| CN104945369A (zh) * | 2015-06-23 | 2015-09-30 | 佛山市赛维斯医药科技有限公司 | 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途 |
| CN104910129A (zh) * | 2015-06-23 | 2015-09-16 | 佛山市赛维斯医药科技有限公司 | 含六甲基苯环和卤代苯结构的黄原酸酯类化合物、其制备方法及用途 |
| CN104892568A (zh) * | 2015-06-23 | 2015-09-09 | 佛山市赛维斯医药科技有限公司 | 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途 |
| CN105001181A (zh) * | 2015-06-24 | 2015-10-28 | 佛山市赛维斯医药科技有限公司 | 一类双酰基苄胺类的ampk激活剂、其制备方法及用途 |
| CN104945371A (zh) * | 2015-06-24 | 2015-09-30 | 佛山市赛维斯医药科技有限公司 | 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途 |
| CN104926755A (zh) * | 2015-06-24 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途 |
| CN105037296A (zh) * | 2015-06-24 | 2015-11-11 | 佛山市赛维斯医药科技有限公司 | 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途 |
| CN104945372A (zh) * | 2015-06-24 | 2015-09-30 | 佛山市赛维斯医药科技有限公司 | 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途 |
| CN104926756A (zh) * | 2015-06-24 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途 |
| CN104926757A (zh) * | 2015-06-24 | 2015-09-23 | 佛山市赛维斯医药科技有限公司 | 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途 |
| CN105541715B (zh) * | 2016-02-02 | 2019-04-09 | 浙江工业大学 | 多取代吡啶-1(2h)-酮衍生物及其合成方法与应用 |
| KR101925020B1 (ko) | 2017-04-21 | 2018-12-04 | 연세대학교 산학협력단 | Mkrn1의 발현 또는 활성 억제제를 유효성분으로 함유하는, 대사성 질환의 예방 및 치료용 약학적 조성물 |
| EA202091897A1 (ru) * | 2018-02-08 | 2020-10-27 | Энио Фарма | Неконденсированные производные тиофена и их применение |
| CN108516972A (zh) * | 2018-05-30 | 2018-09-11 | 王丽萍 | 一种goat抑制剂及其在肥胖和糖尿病中的应用 |
| KR102663976B1 (ko) * | 2018-11-16 | 2024-05-09 | 폭셀 에스아 | 티에노피리돈 유도체의 1수화물 칼륨염 및 이의 제조 방법 |
| US20220184172A1 (en) * | 2019-04-19 | 2022-06-16 | The Regents Of The University Of California | Ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis |
| WO2021037702A1 (en) | 2019-08-28 | 2021-03-04 | Poxel | Pharmaceutical combination of a specific thienopyridone derivative with an fxr agonist for the treatment of liver diseases |
| EP4065104A1 (en) * | 2019-11-27 | 2022-10-05 | Société des Produits Nestlé S.A. | Dibenzopyran ampk activator compounds, compositions, methods and uses thereof |
| MX2022011938A (es) * | 2020-03-26 | 2023-01-04 | Poxel | Uso de un derivado de tienopiridona en el tratamiento de la adrenoleucodistrofia o adrenomieloneuropatia. |
| WO2021198284A1 (en) | 2020-03-30 | 2021-10-07 | Poxel | Use of a thienopyridone derivative in the treatment of cardiovascular diseases |
| ES3010512T3 (en) | 2020-03-30 | 2025-04-03 | Poxel | Use of a thienopyridone derivative in the treatment of diabetic nephropathy |
| KR20220163978A (ko) * | 2020-04-02 | 2022-12-12 | 폭셀 | 상염색체 우성 다낭 신질환 (adpkd) 의 치료에서의 티에노피리돈 유도체의 용도 |
| WO2021204751A1 (en) | 2020-04-06 | 2021-10-14 | Poxel | Pharmaceutical combination for the treatment of liver diseases |
| WO2021204755A1 (en) | 2020-04-06 | 2021-10-14 | Poxel | Pharmaceutical combination for the treatment of liver diseases |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN116322663A (zh) | 2020-09-30 | 2023-06-23 | 比奥维拉迪维治疗股份有限公司 | Ampk激活剂及其使用方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4444815A1 (de) * | 1994-12-15 | 1996-06-20 | Merck Patent Gmbh | Thienopyridone |
| US7119205B2 (en) | 2003-05-16 | 2006-10-10 | Abbott Laboratories | Thienopyridones as AMPK activators for the treatment of diabetes and obesity |
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| EP1754483A1 (en) | 2005-08-18 | 2007-02-21 | Merck Sante | Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them |
| KR101630466B1 (ko) * | 2008-04-11 | 2016-06-14 | 메르크 파텐트 게엠베하 | Ａｍｐ-활성화 단백질 키나아제(ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체 |
| KR101648593B1 (ko) | 2008-05-05 | 2016-08-16 | 메르크 파텐트 게엠베하 | Ａｍｐ-활성화된 단백질 키나아제 (ａｍｐｋ) 활성화제로서의 티에노피리돈 유도체 |
-
2012
- 2012-06-29 EP EP12305775.4A patent/EP2679591A1/en not_active Ceased
-
2013
- 2013-06-28 PL PL13732533T patent/PL2867240T3/pl unknown
- 2013-06-28 EA EA201500064A patent/EA026300B1/ru not_active IP Right Cessation
- 2013-06-28 ME MEP-2016-240A patent/ME02537B/me unknown
- 2013-06-28 JP JP2015519153A patent/JP5972460B2/ja active Active
- 2013-06-28 ES ES13732533.8T patent/ES2603737T3/es active Active
- 2013-06-28 AU AU2013283239A patent/AU2013283239B2/en active Active
- 2013-06-28 PT PT137325338T patent/PT2867240T/pt unknown
- 2013-06-28 DK DK13732533.8T patent/DK2867240T3/en active
- 2013-06-28 HR HRP20161482TT patent/HRP20161482T1/hr unknown
- 2013-06-28 RS RS20160977A patent/RS55308B1/sr unknown
- 2013-06-28 MX MX2014016107A patent/MX359221B/es active IP Right Grant
- 2013-06-28 EP EP13732533.8A patent/EP2867240B1/en active Active
- 2013-06-28 CA CA2876789A patent/CA2876789C/en active Active
- 2013-06-28 IN IN2661MUN2014 patent/IN2014MN02661A/en unknown
- 2013-06-28 US US14/411,690 patent/US9284329B2/en active Active
- 2013-06-28 HU HUE13732533A patent/HUE030946T2/en unknown
- 2013-06-28 BR BR112014032526-0A patent/BR112014032526B1/pt active IP Right Grant
- 2013-06-28 SI SI201330379A patent/SI2867240T1/sl unknown
- 2013-06-28 KR KR1020157002599A patent/KR101704448B1/ko active Active
- 2013-06-28 CN CN201710493350.XA patent/CN107266467A/zh active Pending
- 2013-06-28 LT LTEP13732533.8T patent/LT2867240T/lt unknown
- 2013-06-28 WO PCT/EP2013/063741 patent/WO2014001554A1/en not_active Ceased
- 2013-06-28 CN CN201380034638.0A patent/CN104395319B/zh active Active
-
2014
- 2014-12-11 IL IL236221A patent/IL236221A/en active IP Right Grant
-
2015
- 2015-01-27 ZA ZA2015/00593A patent/ZA201500593B/en unknown
-
2016
- 2016-11-09 CY CY20161101141T patent/CY1118213T1/el unknown
- 2016-11-17 SM SM201600418T patent/SMT201600418B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014016107A (es) | Derivados de tienopiridona utiles como activadores de ampk. | |
| MX2018005193A (es) | Proteinas de doble funcion y composicion farmaceutica que comprende las mismas. | |
| EA201391737A1 (ru) | Новые соединения в качестве ингибиторов диацилглицеролацилтрансферазы | |
| EP3212221A4 (en) | Efficient delivery of therapeutic molecules in vitro and in vivo | |
| EP3204032A4 (en) | Efficient delivery of therapeutic molecules in vitro and in vivo | |
| IN2014MN00986A (it) | ||
| IN2012MN02591A (it) | ||
| DK3444261T3 (da) | 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser | |
| PH12015500407A1 (en) | Methods of treating hypertriglyceridemia | |
| IN2015DN00376A (it) | ||
| IL234133B (en) | A medical preparation for the prevention and treatment of non-alcoholic fatty liver disease | |
| CL2014001838A1 (es) | Compuestos derivados de fluormetil-5,6-dihidro-4h-[1,3]oxazin-2-ilamina, como inhibidores de la bace1; su proceso de obtencion; composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de alzheimer, esclerosis lateral amiotrofica, cancer, enfermedades cardiovasculares y enfermedades gastrointestinales, entre otras. | |
| EE201300007A (et) | Kombineeritud ravimkoostis diabeedi ning ainevahetushirete raviks | |
| ZA201200944B (en) | Pharmaceutical compositions for the treatment of cancer and other diseases or disorders | |
| PH12015502108A1 (en) | Pharmaceutical combination drug | |
| AU2012334804A8 (en) | Modulators of C3a receptors | |
| EP3328388A4 (en) | PHARMACEUTICAL PREPARATION FOR IMPROVING THE INPUT AND POSTPRANDIAL HYPOGLYKEMIC EFFECT OF INSULIN | |
| IL238411A0 (en) | Compositions of medicinal plants for the prevention and treatment of tnf-α related diseases | |
| PH12013502403A1 (en) | Novel compounds as diacylglycerol acyltransferase inhibitors | |
| UA112981C2 (uk) | Варіант людського gdnf | |
| UA115307C2 (uk) | Застосування лікарського засобу, що містить рекомбінантний лектин омели для лікування раку шкіри | |
| PH12016501553B1 (en) | Metadoxine for use in the treatment of liver diseases, and metadoxine extended release formulations | |
| IN2013DN10341A (it) | ||
| CN302073076S (zh) | 注射器（1） | |
| TN2013000185A1 (en) | Inhibitors of apoptosis and uses thereof |